You see a filtered list - Keywords: CRC1382-Project B05
[1]Y. Wen, J. Lambrecht, C. Ju, F. Tacke,
"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities", Cellular & molecular immunology, vol. 18, no. 1, 2021, pp. 45–56.
[bibtex] [url] [doi]
[2]F. Tacke, R. Weiskirchen,
"Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis", Annals of translational medicine, vol. 9, no. 8, 2021, pp. 729.
[bibtex] [url] [doi]
[3]A. Schippers, J. Hübel, F. Heymann, T. Clahsen, S. Eswaran, S. Schlepütz, R. Püllen, N. Gaßler, K. Tenbrock, F. Tacke, N. Wagner,
"MAdCAM-1/α4β7 Integrin-Mediated Lymphocyte/Endothelium Interactions Exacerbate Acute Immune-Mediated Hepatitis in Mice", Cellular and Molecular Gastroenterology and Hepatology, vol. 11, no. 4, 2021, pp. 1227–1250.el.
[bibtex] [url] [doi]
[4]S. Roohani, F. Tacke,
"Liver Injury and the Macrophage Issue", International journal of molecular sciences, vol. 22, no. 14, 2021, pp. 7249.
[bibtex] [url] [doi]
[5]M. Peiseler, F. Tacke,
"An Unexpected Line of Defense", Hepatology, 2021.
[bibtex] [url] [doi]
[6]M. Peiseler, F. Tacke,
"Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma", Cancers, vol. 13, no. 4, 2021, pp. 730.
[bibtex] [url] [doi]
[7]J. Lambrecht, M. Porsch-Özçürümez, J. Best, F. Jost-Brinkmann, C. Roderburg, M. Demir, F. Tacke, R. Mohr,
"The APAC Score", Journal of Clinical Medicine, vol. 10, no. 15, 2021, pp. 3392.
[bibtex] [url] [doi]
[8]J. Lambrecht, F. Tacke,
"Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease", Frontiers in immunology, vol. 11, 2021, pp. 634409.
[bibtex] [url] [doi]
[9]B. Kurt, L. Bündgens, T. Wirtz, S. H. Loosen, M. Schulze-Hagen, D. Truhn, J. F. Brozat, S. Abu Jhaisha, P. Hohlstein, G. Koek, R. Weiskirchen, C. Trautwein, F. Tacke, K. Hamesch, A. Koch,
"Serum Perilipin 2 (PLIN2) Predicts Multiple Organ Dysfunction in Critically Ill Patients", Biomedicines, vol. 9, no. 9, 2021, pp. 1210.
[bibtex] [url] [doi]
[10]T. Wirtz, L. Buendgens, R. Weiskirchen, S. H. Loosen, N. Haehnsen, T. Puengel, S. Abu Jhaisha, J. F. Brozat, P. Hohlstein, G. Koek, A. Eisert, R. Mohr, C. Roderburg, T. Lüdde, C. Trautwein, F. Tacke, A. Koch,
"Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients", Diagnostics, vol. 10, no. 11, 2020.
[bibtex] [url] [doi]
[11]T. Wirtz, S. H. Loosen, L. Buendgens, B. Kurt, S. Abu Jhaisha, P. Hohlstein, J. F. Brozat, R. Weiskirchen, T. Lüdde, F. Tacke, C. Trautwein, C. Roderburg, A. Koch,
"Low Myostatin Serum Levels Are Associated with Poor Outcome in Critically Ill Patients", Diagnostics: open access journal, vol. 10, no. 8, 2020.
[bibtex] [url] [doi]
[12]S. Torres, Z. Abdullah, M. J. Brol, C. Hellerbrand, M. Fernandez, R. Fiorotto, S. Klein, P. Königshofer, C. Liedtke, S. Lotersztajn, Y. A. Nevzorova, R. Schierwagen, T. Reiberger, F. E. Uschner, F. Tacke, R. Weiskirchen, J. Trebicka,
"Recent Advances in Practical Methods for Liver Cell Biology", International journal of molecular sciences, vol. 21, no. 6, 2020, pp. 2027.
[bibtex] [url] [doi]
[13]C. Roderburg, A. Wree, M. Demir, M. Schmelzle, F. Tacke,
"The role of the innate immune system in the development and treatment of hepatocellular carcinoma", Hepatic Oncology, vol. 7, no. 1, 2020, pp. 11 Seiten.
[bibtex] [url] [doi]
[14]K. C. Reimer, A. Wree, C. Roderburg, F. Tacke,
"New drugs for NAFLD", Hepatology international, vol. 14, no. 1, 2020, pp. 8–23.
[bibtex] [url] [doi]
[15]T. Puengel, F. Tacke,
"Editorial: prevalence, progression rates and mortality predictors of non-alcoholic fatty liver disease reflected by German statutory health insurance data", Alimentary pharmacology & therapeutics, vol. 52, no. 8, 2020, pp. 1412–1413.
[bibtex] [url] [doi]
[16]T. Puengel, S. De Vos, J. Hundertmark, M. Kohlhepp, N. Guldiken, P. Pujuguet, M. Auberval, F. Marsais, K. F. Shoji, L. Saniere, C. Trautwein, T. Lüdde, P. Strnad, R. Brys, P. Clément-Lacroix, F. Tacke,
"The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis", Journal of Clinical Medicine, vol. 9, no. 4, 2020, pp. 1140.
[bibtex] [url] [doi]
[17]J. C. Mossanen, T. U. Jansen, J. Pracht, A. Liepelt, L. Bündgens, C. Stoppe, A. Goetzenich, T. Simon, R. Autschbach, G. Marx, F. Tacke,
"Elevated circulating CD14++CD16+ intermediate monocytes are independently associated with extracardiac complications after cardiac surgery", Scientific reports, vol. 10, 2020, pp. 947.
[bibtex] [url] [doi]
[18]I. Lurje, L. Hammerich and F. Tacke,
"Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer", International journal of molecular sciences, vol. 21, no. 19, 2020, pp. 7378.
[bibtex] [url] [doi]
[19]A. Liepelt, P. Hohlstein, H. Gussen, J. Xue, A. C. Aschenbrenner, T. Ulas, L. Bündgens, K. T. Warzecha, M. Bartneck, T. Lüdde, C. Trautwein, J. L. Schultze, A. Koch, F. Tacke,
"Differential Gene Expression in Circulating CD14+ Monocytes Indicates the Prognosis of Critically Ill Patients with Sepsis", Journal of Clinical Medicine, vol. 9, no. 1, 2020, pp. 127.
[bibtex] [url] [doi]
[20]S. Lefere, T. Püngel, J. Hundertmark, C. Penners, A. K. Frank, A. Guillot, K. de Muynck, F. Heymann, V. Adarbes, E. Defrêne, C. Estivalet, A. Geerts, L. Devisscher, G. Wettstein, F. Tacke,
"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages", Journal of hepatology, vol. 73, no. 4, 2020, pp. 757–770.
[bibtex] [url] [doi]
[21]S. Lefere, L. Devisscher and F. Tacke,
"Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis", Expert opinion on investigational drugs, vol. 29, no. 2, 2020, pp. 89–92.
[bibtex] [url] [doi]
[22]J. Lambrecht, L. A. van Grunsven and F. Tacke,
"Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis", Expert opinion on pharmacotherapy, vol. 21, no. 13, 2020, pp. 1637–1650.
[bibtex] [url] [doi]
[23]J. Hundertmark, F. Tacke,
"How effective are nonalcoholic fatty liver disease models for drug discovery?", Expert opinion on drug discovery, vol. 15, no. 11, 2020, pp. 1237–1240.
[bibtex] [url] [doi]
[24]A. Guillot, M. S. Kohlhepp, A. Bruneau, F. Heymann, F. Tacke,
"Deciphering the Immune Microenvironment on A Single Archival Formalin-Fixed Paraffin-Embedded Tissue Section by An Immediately Implementable Multiplex Fluorescence Immunostaining Protocol", Cancers, vol. 12, no. 9, 2020, pp. 2449.
[bibtex] [url] [doi]
[25]A. Guillot, F. Tacke,
"The Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNA‐223 to Macrophages", Hepatology, vol. 71, no. 2, 2020, pp. 749–751.
[bibtex] [url] [doi]
[26]L. Buendgens, E. Yagmur, A. Ginsberg, R. Weiskirchen, T. Wirtz, S. A. Jhaisha, A. Eisert, T. Lüdde, C. Trautwein, F. Tacke, A. Koch,
"Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short-Term and Overall Mortality during a Two-Year Follow-Up", Mediators of inflammation, vol. 2020, 2020, pp. 7184803.
[bibtex] [url] [doi]
[27]F. Benz, A. Bogen, M. Praktiknjo, C. Jansen, C. Meyer, A. Wree, M. Demir, S. Loosen, M. Vucur, R. Schierwagen, F. Tacke, J. Trebicka, C. Roderburg,
"Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis", PLoS one, vol. 15, no. 4, 2020, pp. e0231701.
[bibtex] [url] [doi]
[28]M. Bartneck, C. Koppe, V. Fech, K. T. Warzecha, M. Kohlhepp, S. Huss, R. Weiskirchen, C. Trautwein, T. Lüdde, F. Tacke,
"Roles of CCR2 and CCR5 for Hepatic Macrophage Polarization in Mice With Liver Parenchymal Cell-Specific NEMO Deletion", Cellular and Molecular Gastroenterology and Hepatology, vol. 11, no. 2, 2020, pp. 327–347.
[bibtex] [url] [doi]
[29]S. Sutti, S. Bruzzì, F. Heymann, A. Liepelt, O. Krenkel, A. Toscani, N. Ramavath, D. Cotella, E. Albano, F. Tacke,
"CX3CR1 Mediates the Development of Monocyte-Derived Dendritic Cells during Hepatic Inflammation", Cells, vol. 8, no. 9, 2019, pp. 1099.
[bibtex] [url] [doi]
[30]S. Loosen, M. F. Schulze-Hagen, P. Bruners, F. Tacke, C. Trautwein, C. K. Kuhl, T. Lüdde, C. Roderburg,
"Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies", Cancers, vol. 11, no. 10, 2019, pp. 1503.
[bibtex] [url] [doi]